Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.
People who received a shortened course of antiviral therapy were less likely to be cured.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
A recent study of the direct-acting antiviral regimen included people who contracted hep C within the previous 12 months.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
These two men both recently discovered that they had hepatitis C, each with a different story about their encounters with insurance.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Among those without cirrhosis, treating for an additional four weeks is unnecessary.
Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.
The two-drug regimen can cure the virus in as little as eight weeks.
Mavyret taken for eight weeks was well tolerated and cured all HIV-positive people without cirrhosis in a recent study
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.